Bionano CMO has 24 BNGO shares withheld for taxes

Bionano Genomics, Inc. Chief Medical Officer Alka Chaubey reported a routine tax-related share withholding.

Rhea-AI Filing Summary

Bionano Genomics, Inc. Chief Medical Officer Alka Chaubey reported a routine tax-related share withholding. On shares that vested from a prior restricted stock unit (RSU) award on June 3, 2026, the company withheld 24 shares of common stock at $1.30 per share to cover tax obligations, rather than issuing those shares. After this tax-withholding disposition, Chaubey directly holds 620 shares of Bionano Genomics common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 24 shares

Exercise Price or Tax Liability 1 txn

Insider Chaubey Alka

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	24	$1.30	$31.20

Holdings After Transaction: Common Stock — 620 shares (Direct)

Footnotes (1)

1. F1. The reporting person is reporting the withholding by the Issuer of an aggregate of 24 shares of common stock in connection with shares that vested on June 3, 2026 pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award.

Key Figures

Shares withheld for taxes: 24 shares Withholding price per share: $1.30 per share Shares held after transaction: 620 shares

3 metrics

Shares withheld for taxes 24 shares Withheld to satisfy tax obligations on RSU vesting June 3, 2026

Withholding price per share $1.30 per share Value used for 24 withheld common shares

Shares held after transaction 620 shares Direct common stock holdings following tax-withholding disposition

Key Terms

restricted stock unit (RSU), tax withholding obligations, tax-withholding disposition, Common Stock

4 terms

restricted stock unit (RSU) financial

"in connection with shares that vested on June 3, 2026 pursuant to an RSU award granted on June 3, 2024"

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

tax withholding obligations financial

"were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award"

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Bionano Genomics (BNGO) report for Alka Chaubey?

Bionano Genomics reported a tax-related share withholding for Chief Medical Officer Alka Chaubey. The company withheld 24 common shares to cover taxes on vested RSUs, a routine administrative transaction rather than an open-market buy or sell.

How many BNGO shares were withheld for Alka Chaubey’s taxes and at what price?

The issuer withheld 24 Bionano Genomics common shares at $1.30 per share to satisfy tax obligations. This occurred when restricted stock units vested and were settled, instead of issuing those shares directly to Alka Chaubey.

Does this BNGO Form 4 show Alka Chaubey selling shares on the market?

No, the Form 4 shows shares withheld for taxes, not an open-market sale. The 24 shares were retained by the company to cover tax obligations tied to vesting restricted stock units granted earlier.

What RSU award is referenced in Alka Chaubey’s BNGO Form 4 filing?

The filing references an RSU award originally granted on June 3, 2024. Shares from this award vested on June 3, 2026, and 24 underlying common shares were withheld by Bionano Genomics to satisfy associated tax withholding obligations.

How many Bionano Genomics shares does Alka Chaubey hold after this Form 4 event?

After the tax-withholding disposition, Alka Chaubey directly holds 620 shares of Bionano Genomics common stock. This figure reflects her direct ownership position immediately following the withholding of 24 shares for tax obligations.

Is the Alka Chaubey BNGO Form 4 transaction considered routine?

Yes, it reflects a routine tax-withholding mechanism tied to RSU vesting. The issuer retained 24 shares instead of issuing them, a standard practice that does not indicate discretionary buying or selling activity by the insider.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 08:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chaubey Alka

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		F(1)		24(1)	D	$1.3	620	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is reporting the withholding by the Issuer of an aggregate of 24 shares of common stock in connection with shares that vested on June 3, 2026 pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)